#153965

Anti-HPV-18 E6phospho

Cat. #153965

Anti-HPV-18 E6phospho

Cat. #: 153965

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 10-12 weeks

Target: HPV E6

Class: Polyclonal

Application: WB

Reactivity: Human papilloma virus

Host: Rabbit

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Lawrence Banks

Institute: International Centre For Genetic Engineering And Biotechnology (ICGEB)

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-HPV-18 E6phospho
  • Research fields: Microbiology
  • Tool sub type: Primary antibody
  • Class: Polyclonal
  • Conjugation: Unconjugated
  • Reactivity: Human papilloma virus
  • Host: Rabbit
  • Application: WB
  • Description: Nearly all cases of cervical cancer are associated with HPV infection, with two types, HPV16 and HPV18, present in 70% of cases. A defining feature of cervical cancers and derived cell lines is the continued expression of two viral oncoproteins, E6 and E7. A defining characteristic of E6 oncoproteins derived from cancer-causing HPV types is the presence of a PDZ binding motif (PBM) at the extreme carboxy terminus of the protein which is absent from E6 proteins derived from the so-called low-risk HPV types. Within this PBM is also a protein kinase A (PKA) phospho-acceptor site, which is thought to negatively regulate the association of E6 with its PDZ domain-containing substrates
  • Immunogen: Peptide: RQERLQRRRETQV

Target Details

  • Target: HPV E6
  • Target background: Nearly all cases of cervical cancer are associated with HPV infection, with two types, HPV16 and HPV18, present in 70% of cases. A defining feature of cervical cancers and derived cell lines is the continued expression of two viral oncoproteins, E6 and E7. A defining characteristic of E6 oncoproteins derived from cancer-causing HPV types is the presence of a PDZ binding motif (PBM) at the extreme carboxy terminus of the protein which is absent from E6 proteins derived from the so-called low-risk HPV types. Within this PBM is also a protein kinase A (PKA) phospho-acceptor site, which is thought to negatively regulate the association of E6 with its PDZ domain-containing substrates

Applications

  • Application: WB

Handling

  • Format: Liquid
  • Unit size: 100 ug
  • Storage buffer: Serum
  • Shipping conditions: Shipping at 4° C

References

  • Boon et al. 2015. J Virol. 89(3):1579-86. PMID: 25410862.
  • Cancer-causing human papillomavirus E6 proteins display major differences in the phospho-regulation of their PDZ interactions.
  • Boon et al. 2013. J Virol. 87(3):1586-95. PMID: 23175360.
  • High-risk human papillomavirus E6 oncoproteins interact with 14-3-3 in a PDZ binding motif-dependent manner.